CASE REPORT article
Front. Hematol.
Sec. Hematopoiesis and Stem Cells
Volume 4 - 2025 | doi: 10.3389/frhem.2025.1657903
Diffuse alveolar hemorrhage in a child with mild hemophilia A who underwent bone marrow transplantation for thalassemia: A Case Report Hoa Thi Kim Nguyen, Lawrence Faulkner, Son Binh Bao Bui, Henrique Manoel Lederman, Nhan Thi Thanh Ho, Tam Thi Dang
Provisionally accepted- 1Hue Central Hospital, Hue, Vietnam
- 2Cure2Children Foundation, Florence-Italy, Florence, Italy
- 3Hue University, Hue, Vietnam
- 4Universidade Federal de Sao Paulo, São Paulo, Brazil
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
ABSTRACT Diffuse alveolar hemorrhage (DAH) is a relatively rare complication of bone marrow transplantation (BMT) associated with a high risk of mortality. It generally occurs in the early post-transplant phase during severe thrombocytopenia; however, since most thrombocytopenic cases do not develop DAH, cofactors are at play. Here, we discuss the case of a 4-year-old male child with mild asymptomatic hemophilia A discovered on routine evaluation pre-BMT, who developed DAH after a fully matched sibling BMT for HbE/Beta-thalassemia. The patient presented on day +21 post-BMT with sudden onset of cough followed one day later by hemoptysis. He had received FVIII supplementation with PTT normalization and FVIII levels of 28%. A chest CT scan showed interstitial lung disease with areas of ground glass bilaterally, mainly in the lower lobes. A radiological diagnosis of DAH was made, and the child was treated with additional FVIII concentrate (Advate), blow-by oxygen supplementation, red blood cells transfusion, platelet transfusion, methylprednisolone, tranexamic acid, and antioxidants (vitamin C and E). He responded well and recovered in a few days. Conclusion: Mild hemophilia associated with DAH post-BMT has never been reported before, however, it should be considered as a potentially treatable cause of DAH after BMT. FVIII levels should be part of the routine workup of children developing DAH post-transplantation. In the presence of thrombocytopenia high FVIII levels of >30-40% might be required to prevent/treat DAH.
Keywords: Diffuse alveolar hemorrhage, Hematopoietic stem cells transplantation, Child, Hemophilia A, Thalassemia
Received: 02 Jul 2025; Accepted: 09 Sep 2025.
Copyright: © 2025 NGUYEN, Faulkner, Bui, Lederman, Ho and Dang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: HOA THI KIM NGUYEN, kimhoa.fmi@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.